ArticleACS omega2026
Sustainable Synthesis of Quinolones and the Main Based-Drug Ivacaftor by
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The classic drug synthesis methods applied by the pharmaceutical industry are a major source of toxic and environmentally harmful waste. Although the continuous search for increasingly effective drugs is essential, chemists and chemical engineers involved in production processes have a responsibility to adopt practices aligned with the principles of green chemistry. In this context, aquiline, a combination of choline chloride (ChCl) and water in a 1:3.33 molar ratio, representing one of the earliest examples of natural deep eutectic solvents (NADES) and water-in-salt (WiS) systems, is explored under different conditions as an environmental reaction medium for the synthesis of several 4-quinolone derivatives. These compounds represent key pharmacophores and essential intermediates in the development of various drugs. Notably, the same reaction system is crucial to obtain Ivacaftor, a commercially available drug for managing cystic fibrosis (CF).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.